title: Receptor tyrosine kinase inhibitors in thyroid cancer.
abstract: Thyroid cancer is frequently associated with the oncogenic conversion of receptor tyrosine kinases (RTKs) or their downstream signalling molecules. Hence, there is a strong biological rationale for assessing the efficacy of RTK blockade to treat patients who are resistant to or not candidates for treatment with radioactive iodine. The first results of clinical trials based on the use of RTK inhibitors in thyroid cancer patients have recently been published. Here we discuss targeting of specific RTKs as a potential therapeutic strategy for the treatment of thyroid cancer.
authors.affiliation: Istituto di Endocrinologia ed Oncologia Sperimentale CNR, 80131 Naples, Italy c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universita' Federico II, 80131 Naples, Italy.
authors.forename: Maria Domenica
authors.initials: MD
authors.lastname: Castellone
authors.forename: Francesca
authors.initials: F
authors.lastname: Carlomagno
authors.forename: Giuliana
authors.initials: G
authors.lastname: Salvatore
authors.forename: Massimo
authors.initials: M
authors.lastname: Santoro
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000201:enzymology
chemical_list: D000911:Antibodies, Monoclonal; D047428:Protein Kinase Inhibitors; D020794:Receptor Protein-Tyrosine Kinases